Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 3
1991 11
1992 5
1993 11
1994 4
1995 8
1996 3
1997 1
1998 3
1999 6
2000 5
2001 2
2002 4
2003 5
2004 2
2005 2
2006 9
2007 9
2008 11
2009 9
2010 12
2011 9
2012 8
2013 15
2014 24
2015 11
2016 15
2017 31
2018 55
2019 80
2020 7
Text availability
Article attribute
Article type
Publication date

Search Results

342 results
Results by year
Filters applied: . Clear all
Page 1
Engineering Natural Killer Cells for Cancer Immunotherapy.
Rezvani K, Rouce R, Liu E, Shpall E. Rezvani K, et al. Mol Ther. 2017 Aug 2;25(8):1769-1781. doi: 10.1016/j.ymthe.2017.06.012. Epub 2017 Jun 28. Mol Ther. 2017. PMID: 28668320 Free PMC article. Review.
Chimeric Antigen Receptor Therapy.
June CH, Sadelain M. June CH, et al. N Engl J Med. 2018 Jul 5;379(1):64-73. doi: 10.1056/NEJMra1706169. N Engl J Med. 2018. PMID: 29972754 Review. No abstract available.
CAR T-cell therapy: Full speed ahead.
Sermer D, Brentjens R. Sermer D, et al. Hematol Oncol. 2019 Jun;37 Suppl 1:95-100. doi: 10.1002/hon.2591. Hematol Oncol. 2019. PMID: 31187533 Review.
Toxicities of chimeric antigen receptor T cells: recognition and management.
Brudno JN, Kochenderfer JN. Brudno JN, et al. Blood. 2016 Jun 30;127(26):3321-30. doi: 10.1182/blood-2016-04-703751. Epub 2016 May 20. Blood. 2016. PMID: 27207799 Free PMC article. Review.
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN, Kochenderfer JN. Brudno JN, et al. Blood Rev. 2019 Mar;34:45-55. doi: 10.1016/j.blre.2018.11.002. Epub 2018 Nov 14. Blood Rev. 2019. PMID: 30528964 Free PMC article. Review.
Managing the toxicities of CAR T-cell therapy.
Neelapu SS. Neelapu SS. Hematol Oncol. 2019 Jun;37 Suppl 1:48-52. doi: 10.1002/hon.2595. Hematol Oncol. 2019. PMID: 31187535 Review.
Targeting EGFRvIII for glioblastoma multiforme.
Yang J, Yan J, Liu B. Yang J, et al. Cancer Lett. 2017 Sep 10;403:224-230. doi: 10.1016/j.canlet.2017.06.024. Epub 2017 Jun 23. Cancer Lett. 2017. PMID: 28649003 Review.
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Neelapu SS, et al. Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19. Nat Rev Clin Oncol. 2018. PMID: 28925994 Free PMC article. Review.
Is autoimmunity the Achilles' heel of cancer immunotherapy?
June CH, Warshauer JT, Bluestone JA. June CH, et al. Nat Med. 2017 May 5;23(5):540-547. doi: 10.1038/nm.4321. Nat Med. 2017. PMID: 28475571 Free article.
Chimeric antigen receptor T cell persistence and memory cell formation.
McLellan AD, Ali Hosseini Rad SM. McLellan AD, et al. Immunol Cell Biol. 2019 Aug;97(7):664-674. doi: 10.1111/imcb.12254. Epub 2019 May 15. Immunol Cell Biol. 2019. PMID: 31009109 Review.
342 results
Jump to page
Feedback